Walden Biosciences
Curt Dewan, CFA is an experienced finance professional with a long career in the industry. Curt began their career in 2005 as an Investment Advisor for Edward Jones. In the same year, they also began working as a Financial Analyst for Canada Post. In 2010, they moved to Hertz as a Financial Planning Analyst. From 2011 to 2019, they held various roles at Shire, including Head of Financial Planning, Director of Corporate Finance, Head of Strategy & Operations, International Commercial, and Head of Finance - Central & Eastern Europe, Middle East & Africa. In 2019, they joined Servier Pharmaceuticals as a Business Development Executive, where they led the due diligence, valuation, and integration of the $1.8B acquisition of the Agios Oncology business. In 2021, they began working as Vice President, Head of Finance for Walden Biosciences.
Curt Dewan, CFA obtained a CAS in Management of Technology from EPFL (École polytechnique fédérale de Lausanne) in 2011. Curt then obtained an MSc in Biomechanics from McGill University in 2002-2004. Prior to that, they obtained a B.Ed in Kinesiology & Biology from McGill University in 1997-2001.
This person is not in any teams
Walden Biosciences
Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We are developing breakthrough medicines targeted directly to the kidney and will be successful through our comprehensive knowledge and understanding of novel kidney-specific biological pathways and our team’s track record in drug discovery. Our goal is to transform the treatment of kidney disease by reversing its progression, enabling and inspiring patients to resume their normal lives. Our culture is collaborative and entrepreneurial, and our team is dynamic and driven by data and innovation. We want to make the best decisions with the best available information, lead by example, and bring transformative medicines to patients in need. Walden is based in the heart of Cambridge, MA between Harvard, Massachusetts Institute of Technology (MIT), and Massachusetts General Hospital.